Department of Anesthesiology, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, Shanghai 200233, China.
Cardiovasc Ther. 2010 Spring;28(1):23-9. doi: 10.1111/j.1755-5922.2009.00115.x.
Pulmonary hypertension is a group of diseases comprising vascular constriction and obstructive changes of the pulmonary vasculature. Phosphodiesterase type 5 inhibitors, for example, sildenafil, can alleviate vascular remodeling in the monocrotaline pulmonary hypertension model in rats. We investigate the mechanisms of sildenafil on the pulmonary vascular remodeling of pulmonary hypertension induced by monocrotaline (MCT) in rats. Thirty Sprague-Dawley rats (weighing 200-220 g) were administered with MCT abdominal cavity injection or equivalent volume of normal saline (NS) (which were treated as C group n = 10) to induce pulmonary hypertension model. Fourteen days later, 20 MCT treated rats were randomly fed with sildenafil (25mg/kg/day) or placebo as S, P group (10 rats for each group), respectively. Another 6 weeks later, mean pulmonary artery pressure (mPAP), index of right ventricular hypertrophy (RV/LV+S) of all animals were measured under general anesthesia. Pulmonary tissue was collected to investigate pathological features of pulmonary arteries and to measure protein expression of ERK(1)/ERK(2) and MKP1. After 6 weeks, there were significant elevated mPAP and RV/LV+S in both P and S groups. The ratio of wall thickness to vessel diameter in pulmonary arteries with diameters <200 microm were increased in both P and S groups. But the ratio of wall thickness to vessel diameter was smaller in S group than that in P group. The phosphorylation level of ERK(1)/ERK(2) were elevated in both P and S groups, but the level of phosphorlation ERK(1)/ERK(2) were lower in S group than that in P group. Intriguingly, the expression level of MKP1 was significantly increased in both S and P groups, while it was higher in S group than that in P group. The sildenafil can decrease mPAP and inhibit the progress of pulmonary vascular remodeling in pulmonary hypertension rats. The ERK-MAP kinase signaling pathway might play a role during this process.
肺动脉高压是一组包含血管收缩和肺血管阻塞性改变的疾病。例如,磷酸二酯酶 5 抑制剂西地那非可减轻大鼠野百合碱肺动脉高压模型中的血管重塑。我们研究了西地那非对野百合碱(MCT)诱导的大鼠肺动脉高压肺血管重塑的作用机制。30 只 Sprague-Dawley 大鼠(体重 200-220g)腹腔注射 MCT 或等量生理盐水(作为 C 组,n=10)诱导肺动脉高压模型。14 天后,20 只 MCT 处理大鼠随机给予西地那非(25mg/kg/天)或安慰剂(S、P 组,每组 10 只)。6 周后,在全身麻醉下测量所有动物的平均肺动脉压(mPAP)和右心室肥厚指数(RV/LV+S)。收集肺组织以研究肺血管的病理特征,并测量 ERK(1)/ERK(2)和 MKP1 的蛋白表达。6 周后,P 组和 S 组的 mPAP 和 RV/LV+S 均显著升高。两组肺动脉直径<200μm 的血管壁厚度与血管直径的比值均增加,但 S 组的比值小于 P 组。两组 ERK(1)/ERK(2)的磷酸化水平均升高,但 S 组的磷酸化水平低于 P 组。S 组和 P 组的 MKP1 表达水平均显著升高,但 S 组的表达水平高于 P 组。西地那非可降低 mPAP 并抑制肺动脉高压大鼠的肺血管重塑进展。ERK-MAP 激酶信号通路在此过程中可能发挥作用。